Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 55Myelodysplastic Syndromes 41Leukemia, Lymphocytic, Chronic, B-Cell 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 39Hodgkin Disease 39Neoplasms, Plasma Cell 38Leukemia 37Leukemia, Myeloid, Acute 36Lymphoma, Non-Hodgkin 35Lymphoma, Follicular 35Lymphoma 35Lymphoma, Mantle-Cell 34Lymphoma, B-Cell, Marginal Zone 33Lymphoma, Large B-Cell, Diffuse 32Burkitt Lymphoma 30Lymphoma, Large-Cell, Immunoblastic 29Leukemia, Myeloid, Chronic-Phase 28Leukemia, Myeloid, Accelerated Phase 28Myeloproliferative Disorders 25Congenital Abnormalities 25Primary Myelofibrosis 23Blast Crisis 22Recurrence 20Dendritic Cell Sarcoma, Interdigitating 19Lymphoma, T-Cell, Cutaneous 18Leukemia, Myelomonocytic, Chronic 18Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 16Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 15Waldenstrom Macroglobulinemia 14Sezary Syndrome 14

Interventions

Melphalan 2Filgrastim 2Fibroblast Growth Factor 7 2Cyclophosphamide 2Amifostine 2sargramostim 1Sirolimus 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Ifosfamide 1Etoposide 1Epoetin Alfa 1Deoxycytidine 1Cytarabine 1Carboplatin 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Antilymphocyte Serum × Plasma cell × Clear all
NCT00317798 2011-08-30

Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma

University of Rochester

Phase 1 Completed
18 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡